Susceptibility of bacterial isolates from complicated skin and skin structure infections to cefazolin, imipenem-cilastatin, ciprofloxacin and ofloxacin.
Liu
H H
HH
Division of Infectious Diseases (W-250), Presbyterian Medical Center, Philadelphia, PA 19104, USA.
Bolash
N K
NK
McAnany
M E
ME
Lynch
R A
RA
D000293:Adolescent; D000328:Adult; D000890:Anti-Infective Agents / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects*; D002437:Cefazolin / Q000494:pharmacology; D015377:Cilastatin / Q000494:pharmacology; D000077728:Cilastatin, Imipenem Drug Combination; D002939:Ciprofloxacin / Q000494:pharmacology; D004338:Drug Combinations; D004359:Drug Therapy, Combination / Q000494:pharmacology*; D005260:Female; D006801:Humans; D015378:Imipenem / Q000494:pharmacology; D008297:Male; D015242:Ofloxacin / Q000494:pharmacology; D017192:Skin Diseases, Bacterial / Q000382:microbiology*; D018461:Soft Tissue Infections / Q000382:microbiology
D000890:Anti-Infective Agents; D004338:Drug Combinations; D015377:Cilastatin; D002939:Ciprofloxacin; D015378:Imipenem; D000077728:Cilastatin, Imipenem Drug Combination; D015242:Ofloxacin; D002437:Cefazolin